Lexicon Announces Publication of Results of Two Studies of LX4211; Gilead Submits NDA for Cobicistat Print E-mail
By Staff and Wire Reports   
Friday, 29 June 2012 18:27
Below is a look at some of the headlines for companies that made news in the healthcare sector on June 29, 2012.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)
announced the publication of results from two initial trials of LX4211 in patients with type 2 diabetes in the online edition of the journal Clinical Pharmacology & Therapeutics. The paper, containing results from both trials, is entitled, "LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients with Type 2 Diabetes in a Randomized, Placebo-controlled Trial," and will also appear in an upcoming print edition of the journal. A link to the online article can be accessed at http://www.nature.com/clpt/journal/vaop/ncurrent/full/clpt201258a.html.

"This publication represents the first peer-reviewed description of SGLT1 inhibition stimulating GLP-1 and PYY release in man," said Dr. Brian Zambrowicz, Lexicon's executive vice president and chief scientific officer. "Since LX4211 also inhibits SGLT2, the rapid and significant glycemic control and metabolic benefits observed may be attributed to effective dual inhibition of these two targets."


Gilead Sciences, Inc. (Nasdaq: GILD)
announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or “boosting” agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.

Cobicistat is also a component of the Quad once-daily single tablet regimen for HIV, which is currently under U.S. and European regulatory review for treatment-naïve adult patients.

Also Friday:

A.P. Pharma, Inc. (OTCBB: APPA.OB)
, a specialty pharmaceutical company, today announced additional data from the Company’s Phase 3 study of APF530 for the prevention of chemotherapy-induced nausea and vomiting (CINV).

Biogen Idec (NASDAQ: BIIB)
and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that they have entered into an exclusive, worldwide option and collaboration agreement under which the companies will develop and commercialize a novel antisense drug for the treatment of myotonic dystrophy type 1 (DM1), which is also known as Steinert disease.

Charles River Laboratories International, Inc. (NYSE: CRL)
will release second-quarter 2012 financial results on Tuesday, August 7th, after the market closes.

CytoSorbents Corporation (OTCBB: CTSO)
, a critical care-focused company using blood purification to modulate the immune system, reduce severe inflammation, and prevent or treat organ failure caused by life-threatening illnesses, announced promising large animal data from a research collaboration with Dr. David Rabkin, Assistant Professor of Surgery, Division of Cardiothoracic Surgery at the University of Washington Medical Center in Seattle, Washington.

Daxor Corporation (NYSE MKT: DXR)
, a medical instrumentation and biotechnology company, has registered as an investment company.

Hamilton Thorne Ltd. (TSX VENTURE: HTL)
, a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today announced that the Company will be showcasing two of its premier clinical products at the 28th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) taking place in Istanbul, Turkey from July 1-4, 2012.

Impax Laboratories, Inc. (NASDAQ: IPXL)
(the “Company”) today announced that Arthur A. Koch, the Company’s Executive Vice President, Finance, and Chief Financial Officer, has informed the Company of his decision to resign from his position with the Company to pursue other opportunities.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)
announced today the publication of results from two initial trials of LX4211 in patients with type 2 diabetes in the online edition of the journal Clinical Pharmacology & Therapeutics.

MDxHealth SA (NYSE Euronext: MDXH)
, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, announced today that it has successfully raised € 10,000,000 million in gross proceeds through a private placement of new shares with investors in various jurisdictions.

Medistem Inc. (PINKSHEETS: MEDS)
announced today notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent covering the use of fat stem cells, and cells associated with fat stem cells for treatment of diseases related to a dysfunctional immune system.

MMRGlobal, Inc. (OTCBB: MMRF)
("MMR"), a leading provider of Personal Health Records (PHRs) through its MyMedicalRecords.com and MMRPro document management and imaging systems, believes the Company will benefit from the U.S. Supreme Court's decision upholding the major elements of the 2010 Affordable Care Act ("ACA").

NanoViricides, Inc. (OTC BB: NNVC)
(the "Company"), announced today that it has raised $5,000,000, drawing down on its previously announced universal registered shelf “Form S-3” offering.

Ohr Pharmaceutical Inc. (OTCBB: OHRP)
today announced that Ohr's existing shareholders exercised 5,299,002 Series H warrants at an exercise price of $0.55 per warrant for gross and net proceeds of $2,914,451.

Osiris Therapeutics, Inc. (NASDAQ: OSIR)
, announced today the expansion of its intellectual property protection around Prochymal® (remestemcel-L).

, today announced that PROLOR scientist Dr. Gili Hart will present data on the company's long-acting clotting factors in preclinical development for the treatment of hemophilia at the 58th Annual Meeting of the Science and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH).

SpectraScience, Inc. (OTCQB: SCIE) (PINKSHEETS: SCIE)
, a San Diego-based medical device company, has begun initial shipments of its WavSTAT4 Optical Biopsy System to PENTAX Europe GmbH under the exclusive, 5-year distribution agreement announced earlier this month.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus